6 days Ago By ABMN Staff
Mariner LLC lessened its stake in shares of TransMedics Group, Inc. ( NASDAQ:TMDX – Free Report ) by 4.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission.
The firm owned 12,156 shares of the company’s stock after selling 512 shares during the period. Mariner LLC’s holdings in TransMedics Group were worth $758,000 at the end of the most recent reporting period. A number of other institutional investors also recently modified their holdings of TMDX.
Atlas Capital Advisors Inc. acquired a new position in shares of TransMedics Group during the 4th quarter valued at $31,000. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the 4th quarter valued at $33,000.
Sachetta LLC bought a new stake in TransMedics Group during the 4th quarter valued at $40,000. AlphaQuest LLC bought a new stake in TransMedics Group during the 4th quarter valued at $52,000. Finally, Arcadia Investment Management Corp MI bought a new stake in TransMedics Group during the 4th quarter valued at $72,000.
Institutional investors and hedge funds own 99.67% of the company’s stock. TransMedics Group Price Performance Shares of NASDAQ:TMDX opened at $90.
19 on Tuesday. The company’s 50-day moving average is $74.67 and its 200 day moving average is $77.
10. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.
33 and a current ratio of 8.20. The company has a market capitalization of $3.
05 billion, a P/E ratio of 95.95 and a beta of 2.14.
TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.
37. Analyst Ratings Changes Check Out Our Latest Research Report on TMDX About TransMedics Group ( Free Report ) TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. ( NASDAQ:TMDX – Free Report ).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter ..
